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3400 words 
 
Key message Box 
- There is no harmless level of cigarette consumption. Even smoking >0-3 cigarettes per day is associated 
with an increased HNC risk 
- This association between low frequency of cigarette consumption and HNC risk is consistent across 
subsites of head and neck cancer and among never alcohol drinkers.  
- Smoking duration plays at least an equal or a stronger role as low frequency of cigarettes smoking in the 
development of HNC. 
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ABSTRACT  
Background: Cigarette smoking is a major risk factor for head and neck cancer (HNC). To our knowledge, 
low cigarette smoking (<10 cigarettes per day) has not been extensively investigated, in fine categories or 
among never alcohol drinkers. 
Methods: We conducted a pooled analysis of individual participant data (IPD) from 23 independent case-
control studies including 19 660 HNC cases and 25 566 controls. After exclusion of subjects using other 
tobacco products including cigars, pipes, snuffed or chewed tobacco and straw cigarettes (tobacco product 
used in Brazil) as well as subjects smoking more than 10 cigarettes per day, 4 093 HNC cases and 13 416 
controls were included in the analysis. The lifetime average frequency of cigarette consumption was 
categorized as follows: never cigarette users, >0-3, >3-5, >5-10 cigarettes per day.  
Results: Smoking >0-3 cigarettes per day was associated with a 50% increased risk of HNC in the study 
population (OR=1.52, 95% CI: 1.21-1.90). Smoking >3-5 cigarettes per day was associated in each 
subgroup from OR=2.01 (95% CI: 1.22-3.31) among never alcohol drinkers to OR=2.74 (95%CI: 2.01-3.74) 
among women and in each cancer site, particularly laryngeal cancer (OR=3.48, 95%CI: 2.40-5.05). 
However, the observed increased risk of HNC for low smoking frequency was not found among smokers with 
smoking duration shorter than 20 years.  
Conclusion: Our results suggest a public health message that low frequency of cigarette consumption 
contributes to the development of HNC. However, smoking duration seems to play at least an equal or a 
stronger role in the development of HNC. 
 
Key words: Head and neck cancer (HNC), low frequency cigarette smoking, risk factors, pooled analysis 
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Introduction 
Cigarette smoking is a well-established risk factor for head and neck cancer (HNC) with a well-defined dose-
response relationship for duration and frequency of use (1,2). Yet, in several epidemiological studies the 
lowest category of tobacco smoking has been defined as smoking <10 cigarettes per day. To our knowledge, 
only three studies have investigated the risk of HNC among participants smoking less than 10 cigarettes per 
day: Polesel et al (3), using cubic regression spline model among male current smokers only (1 241 upper 
aerodigestive tract (UADT) cancer cases and 2 835 controls) showed evidence for an increased risk of oral 
cavity and pharyngeal cancer beginning at 2 cigarettes per day, and an increased risk of laryngeal cancer 
beginning at 5 cigarettes per day. Tuyns et al (4) showed evidence for an increased risk of endolarynx 
(OR=2.37, 95% CI: 1.3, 4.3) and of hypopharynx (OR=4.18, 95% CI: 1.9, 9.3) associated with smoking 1 to 7 
cigarettes per day compared to never smokers, adjusted for alcohol consumption. McLaughlin et al (5) 
reported similar results in a 1 to 9 cigarettes per day category: OR=5.2 (95%CI: 1.8,15) for pharyngeal 
cancer. However, no analyses were conducted among finer cigarette smoking frequency categories or 
specific subgroups such as never alcohol drinkers.  
Few studies have been able to address the risk of HNC among smokers of few cigarettes per day 
due to the inadequate number of cases smoking less than 10 cigarettes per day. Consequently, either spline 
regression models needed to be utilized or broader categories of smoking frequency were used.  
The International Head and Neck Cancer Epidemiology (INHANCE) consortium was established in 
2004 to explore the potential head and neck risk factors that were difficult to evaluate in individual studies 
due to limited sample size. To participate in the INHANCE consortium, studies should provide individual 
participant data, with data available on demographic and tumor characteristics, alcohol consumption, and 
tobacco use habits (6,7). Individual participant data allow re-analysis with new hypotheses formulated, 
various adjustments and specific subgroup analyses.  
The purpose of this study is to assess the dose-response relationship between cigarette smoking 
and the risk of HNC among subjects smoking less than 10 cigarettes per day with better precision while 
taking into account potential confounding and effect modifications. This analysis on low frequency of 
cigarette consumption was proposed to be performed within the INHANCE consortium database. 
 
Methods 
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The version 1.4 of the INHANCE pooled dataset is an update of the version 1.0, previously described by 
Hashibe et al (7). At the time of this analysis, the INHANCE V1.4 dataset included 29 case-control studies 
with 21 373 HNC cases and 29 548 controls. 
For this analysis, we pooled data from 23 studies (Table1) with available information on cigarette, 
cigar and pipe smoking status, duration and frequency, satisfying the criteria for the random effect model 
used (each category of the low frequency of cigarette smoking variable should have at least one case or one 
control) including 19 660 cases and 25 566 controls. We then excluded subjects missing information for age, 
sex, race and cases missing the subsite of HNC (110 cases and 127 controls). Then, to focus on the 
association with low cigarette smoking frequency and to avoid residual effects from other tobacco product, 
users of cigar, pipe, chew or snuff tobacco or straw cigarettes were excluded (3 206 cases and 2 913 
controls). As the aim of the paper is to focus on low frequency of cigarette smoking, subjects smoking more 
than 10 cigarettes per day were excluded (12 251 cases and 9 110 controls). The final analysis dataset 
included 4 093 HNC cases and 13 416 controls from the 23 studies. Of the 3,260 HNC cases from studies 
with histological information, 3 067 (94.1%) were squamous cell carcinoma (SCC).  
The number of cigarettes per day was defined differently among studies. It was either a lifetime 
average consumption (the Houston, Tampa, Puerto Rico, Rome, North Carolina (1994-1997), Milan (1984-
1989), Aviano, Italy multicenter, Switzerland, New York multicenter, Iowa, US multicenter, Seattle-Leo, 
Western Europe, North Carolina (2002-2006) studies) or a period specific frequency, usually by decades, 
changing habits or changing brand period (the Los Angeles, Seattle, Boston, Central Europe, International 
multicenter, Latin America, Sao Paulo, Germany-Heidelberg) In the pooled analysis we used the lifetime 
average daily consumption by adding the information when it was directly available or calculating it by 
weighing each frequency of cigarette smoking by its specific duration of consumption. We also added a 
reference that provides more details (Hashibe et al, 2009) (8). 
The frequency of cigarette smoking was defined in four categories (Never cigarette users, >0-3 
cigarettes per day, >3-5, >5-10) and analyses were conducted in the overall study population, among never 
alcohol users, for subsites of HNC (oral cavity, hypopharynx, oropharynx, oral cavity/pharynx not specified, 
and larynx, detailed in Hashibe et al, 2007) (7), by gender and among the different categories of duration of 
cigarette smoking and age at start of smoking cigarettes. One additional variable was created: combining low 
frequency of cigarette smoking categories and duration of cigarette smoking categories (<=10 years, 10-20 
years and >20years).  
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Statistical analysis 
The association of low frequency cigarette smoking with HNC was assessed by estimating odds ratios (OR) 
and 95% confidence intervals (CI) based on unconditional logistic regression models. To calculate summary 
estimates of associations, the study-specific estimates were included in a multivariate two-stage random-
effects logistic regression model that included the DerSimonian and Laird estimator (9), which allows for 
unexplained sources of heterogeneity among studies. Pooled odds ratios were also estimated with a fixed-
effects logistic regression model that adjusted for age (5 years categories), sex, education (categorical), 
race/ethnicity, study/study center and number of alcoholic drinks per day (categorical). Number of drinks per 
day was set as a categorical variable to minimize the impact of the highest values. The Latin America and 
Sao Paulo studies did not assess race/ethnicity, thus we classified the subjects as a separate category “Latin 
Americans-Brazilian”. 
Since 246 cases and 454 controls were missing education level, we applied multiple imputations 
(five imputations) with the PROC MI procedure in SAS. We assumed that the education data were missing at 
random (i.e. whether education was missing or not did not depend on any other unobserved or missing 
values (10). We used the logistic regression model (11) to predict education level with age, sex, 
race/ethnicity, study center, and case/control status within each region (Europe, North America, Latin 
America and Asia) separately. The logistic regression results to assess summary estimates for low cigarette 
smoking frequency for the five imputations were combined by the PROC MIANALYZE procedure.  
We tested for heterogeneity across studies, using a likelihood ratio test derived from fitting a model 
with and a model without a product term between low cigarette smoking and the study indicator. Then, we 
compared twice the difference of the log likelihood ratio of these two models, with a Chi square distribution. 
The degree of freedom of the test was the number of studies minus one. When heterogeneity between 
studies was detected (p<0.05), the random effect estimates were reported, otherwise the fixed effects 
estimates were reported. We examined whether the results from the two-stage random effects model and the 
fixed effects logistic regression model were comparable in magnitude of effect. When random effect 
estimates were estimated, individual studies missing cases or controls for any of the low cigarette 
consumption frequency categories were excluded, in order to have homogenous contribution of studies 
across categories. We also conducted influence analysis, where each study was excluded one at a time to 
assure that the statistical significance and magnitude of the overall summary estimate was not dependent on 
any particular study. The trend test used for the analysis was a Cochrane-Armitage test. 
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A specific analysis was conducted after exclusion of oropharyngeal cancer cases. There is strong 
evidence that a large proportion of oropharyngeal cancers are caused by human papillomaviruses and are 
not related to tobacco smoking (12,13). Analyses were then stratified by cancer site, age category (≤ 45, 46 
– 50, 51 – 60, 61 – 70, and >70 years), sex, race/ethnicity, education level, source of control subjects 
(hospital-based versus population-based), and geographic region (Europe, North America, South/ Central 
America, others). We also repeated the analyses restricting the cases to SCC histology within the set of 
studies that had collected histology information.  
.
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Results 
The distributions of cases and controls by selected characteristics are reported in Table 2. The 
proportion of cigarette smokers smoking a lifetime average <5 cigarettes per day was 72.8% among controls 
and 27.2% among cases. The highest proportion of smokers of <5 cigarettes per day were from the Boston 
study (63.5%) and the Los Angeles study (57.4%). Women were more likely than men to smoke a lifetime 
average of <5 cigarettes per day (43.0% vs 33.8%). Participants smoking <5 cigarettes per day were more 
likely to start smoking at a later age, for a shorter duration and to be former smokers (participants who 
stopped smoking for more than 1 year before answering the questionnaire) compared to participants 
smoking more than 5 cigarettes per day (p<0.01 for each comparison).  
HNC risk increased with greater smoking frequency in the overall study population, after exclusion of 
oropharyngeal cancer cases and among never alcohol drinkers (p for trend <0.01; Table 3). The OR for the 
category of >0-3 cigarettes/day was 1.52 (95% CI: 1.21, 1.90) for the overall study population and 1.35 (95% 
CI: 0.83, 2.18) among never alcohol drinkers. The association between smoking >3-5 cigarettes per day and 
the risk of HNC was observed among the overall study population (OR=2.14, 95% CI: 1.73, 2.65) and among 
never alcohol drinkers (OR=2.01, 95% CI: 1.22, 3.31). 
Results by HNC subsite demonstrated the strongest dose-response relationship for hypopharyngeal 
and laryngeal cancer (p for trend <0.01; Table 4). For these subsites, the OR for smokers of >0-3 category 
cigarettes/day was 2.43 (95% CI: 1.23, 4.79) for hypopharynx and 2.68 (95% CI: 1.82, 3.95) for larynx. 
Although the point estimates were slightly higher among women than men, the 95% CIs overlapped 
(Table 5). We observed that women smoking >0-3 cigarettes per day had an increased risk of HNC 
(OR=1.77, 95% CI: 1.30, 2.40) compared to never smokers. For the combination of frequency and duration 
of smoking, we observed an association between HNC and each stratum of the low frequency of cigarette 
consumption with the highest stratum of smoking duration (Table 6).. Figure 1 shows a forest plot of the 
study specific estimates for the risk of HNC associated with smoking 3 to 5 cigarettes per day. All studies but 
Switzerland, Tampa and Los Angeles showed an increased risk of HNC for smoking 3 to 5 cigarettes per 
day. There was also an increased risk of smoking >0 to 3 cigarettes per day among current smokers 
(OR=2.07, 95% CI: 1.53, 2.81) and among former smokers (OR=1.32, 95% CI: 1.05, 1.66).  
An analysis stratified by study design showed positive monotonic trends of increasing risks with 
increasing frequency of cigarette smoking for both hospital-based (n=15) and population-based (n=9) studies 
(the Western Europe study include studies with both population based and hospital based controls), with a 
slightly weaker trend in population-based studies (OR=1.64, 95% CI: 0.90, 3.00; OR =1.93, 95% CI: 1.31, 
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2.85; OR=2.51, 95% CI: 1.50, 4.18 for >0-3, >3-5, >5-10 cigarettes/day respectively; p for trend <0.01). 
When the analysis by region was conducted, an apparent positive trend of increasing risks with increasing 
frequency of cigarette smoking was observed in each region. Such relationship was found to be strongest in 
Europe and Latin America. The risk of HNC for smoking >0 to 3 cigarette per day was OR=1.82 (95% CI: 
1.15, 2.86) in Europe and OR=1.98 (95%CI: 1.15, 3.39) in Latin America. Analyses restricted to squamous 
cell carcinoma yielded similar results (see table appendix). 
We additionally adjusted, when the information was available, for BMI (all studies except for Rome, 
Seattle, International multicenter, Iowa, Central Europe, Sao Paulo, Germany-Heidelberg) and for family 
history of HNC (all studies except for Rome, Seattle, New York multicenter, Iowa, Western Europe and 
Seattle-Leo). The magnitudes of the associations were similar to those observed without the additional 
adjustments (see table appendix). Analysis of passive smoking was not conducted as this information was 
only available in 6 studies (Central Europe, Latin America, Puerto Rico, Tampa, Los Angeles and Houston), 
and this would have resulted in a restricted number of cases and controls. However, based on our previous 
analysis on passive smoking (14), the modest association with passive smoking was observed among never 
tobacco users. Thus, we suspect the dose-response relationship among smokers presented here would not 
be significantly biased" 
Finally, we conducted sensitivity analyses to assess whether or not one or several studies had a 
strong influence on the observed associations. When we omitted each study from the analysis one at a time, 
the Aviano and the Tampa studies accounted for heterogeneity the most. When the Aviano study was not 
included, the summary estimate for smoking 3 to 5 cigarettes per day compared to never smokers was 2.04 
(95% CI: 1.69, 2,46) and when the Tampa study was not included, the summary estimate was 2.18 (95% CI: 
1.76, 2,69) as compared to the overall summary estimate of 2.14 (95% CI: 1.73, 2.65). When both studies 
were excluded from the summary estimate, the OR was 2.06 (95% CI: 1.71 to 2.49).  
The sensitivity analysis was also conducted for smoking >0 to 3 cigarettes per day.  
When we omitted each study from the analysis one at a time, the Seattle and the North Carolina (hospital 
based) studies accounted for heterogeneity the most. When the Seattle study was not included, the 
summary estimate for smoking >0 to 3 cigarettes per day compared to never smokers was 1.55 (95% CI: 
1.24, 1.95) and when the North Carolina study was not included, the summary estimate was 1.50 (95% CI: 
1.19, 1.88) as compared to the overall summary estimate of 1.52 (95% CI: 1.21, 1.90). When both studies 
were excluded from the summary estimate, the OR was 1.54 (95% CI: 1.22 to 1.93). 
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Discussion 
The ability to pool individual data from studies allowed us to detect an increased risk of HNC with smoking 
less than 10 cigarettes more precisely than it has been reported previously by Tuyns et al (4) and 
McLaughlin et al (5) and highlighted an approximately one and half-fold increased risk of HNC for smoking 
>0 to 3 cigarettes per day and a more than two-fold increased risk of HNC for smoking >3 to 5 cigarettes per 
day.. This also corroborates the results reported by Polesel et al (3) that there is an increased risk regardless 
of the number of cigarettes smoked per day. Polesel showed evidence for an increased OR of UADT cancer 
for smoking 2 cigarettes per day. The present analysis provides additional details for the finer categories of 
smoking frequency with adequate sample size. 
From a methodological point of view we decided to investigate the frequency of cigarette smoking as a 
categorical variable with fine categories instead of a continuous variable. Even though using a continuous 
variable might increase the precision of the estimates, it implies to make some assumptions on the shape of 
the slope and might introduce mis-specification bias. There is no need for such assumptions when using a 
categorical variable. The large number of cases and controls provides for sufficient precision, and keeps the 
results straight forward for interpretation. 
The higher increased risk of laryngeal cancer with cigarette smoking compared to the other head 
and neck subsites is consistent with the previous findings (12,13) and with the previous reports from 
INHANCE studies that active smoking is a stronger risk factor for laryngeal cancers than for oral cavity 
cancer among never alcohol drinkers (7).  
. The analysis combining the smoking frequency with smoking duration is consistent with the 
previous observations that duration of smoking seems to play at least an equal or a stronger role in the 
development of HNC (4) even among never alcohol drinkers.  
A potential limitation with regards to the data pooling was the variation of definition for “ever cigarette 
smokers” (among whom the frequency of cigarette smoking was measured) used in the different studies: 
ever smoked, smoked ≥100 cigarette in a lifetime, smoked 1 cigarette/day for ≥1 year or 6 months, smoked 1 
cigarette/week for >1 year or smoked ½ pack/week for ≥1 year. However, these different classifications are 
relatively minor and likely to be non-differential between cases and controls. Thus, this might lead to an 
underestimation of the assessment. In addition, some individuals with very minimal cigarette use may have 
been categorized as ‘‘never cigarette users’’ in the analysis due to the definition or the wording of the 
questions. The studies with higher threshold for the classification were the Tampa study (smoking cigarettes 
less than once a day for <1 year as never users of cigarettes) and Latin America study (<1 cigarette per day 
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for 1 year as never cigarette smokers). However, the ORs for the lowest category of smokers (>0-3 per day) 
were not consistently lower or higher for these studies compared to the others included in our pooled 
analysis.  
Recall bias may be another limitation for our pooled analysis because information about cigarette 
smoking and the other exposures was collected for cases after the diagnosis of HNC. However, we observed 
associations between low frequency cigarette smoking in both hospital-based and population-based studies, 
which may be susceptible to recall bias in different degrees. In addition, there might be residual confounding 
by the other risk factors. However, our study sample size allowed us to investigate the association among 
never alcohol drinkers to eliminate the possible residual confounding by alcohol drinking. Additionally, further 
adjustment for body mass index and family history of HNC did not support that the observed association 
could be accounted for by these factors. Although heterogeneity across studies was important, in the >0-3 
and 3 to 5 cigarettes per day, the sensitivity analyses showed that exclusion of studies contributing the most 
in the heterogeneity did not lead to major changes in the estimates for both categories.  
Finally, as specified in the method section, analyses were conducted on data from studies 
participating in the INHANCE consortium. Some published and unpublished studies might not be included 
but publication bias is not a concern for this type of analysis because we did not select studies from the 
literature. Additionally, the large sample size and the quality of the studies included allow our estimates to be 
accurate. 
In summary, this pooling project provides evidence for a carcinogenic consequence of cigarette 
smoking at low frequency. The results of this study send a public health message to the community: there is 
no harmless level of cigarette consumption, even smoking >0-3 cigarettes per day is associated with an 
increased HNC risk. However, smoking duration seems to play at least an equal or a stronger role in the 
development of HNC in light smokers. 
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Study Location  (Reference†) Recruitment period 
 Cases Control‡ 
Source Participatio
n rate, % 
Age eligibility, 
years Total  Source Participation rate, % Total 
Europe          
Milan, Italy  1984–1989 Hospital 95§ <80 416  Hospital (unhealthy) 95§ 1,531 
Aviano, Italy  1987–1992 Hospital >95§ >18 482  Hospital (unhealthy) 95§ 855 
Italy (Aviano, Milan, Latina)║  1990–1999 Hospital >95 18–80 1,261  Hospital  (unhealthy) >95 2,716 
Switzerland  1991–1997 Hospital >95 <80 516  Hospital (unhealthy) >95 883 
Central Europe (Banska Bystrica, 
Bucharest, Budapest, Lodz, 
Moscow)║ 
1998–2003 Hospital 96 ≥15 762  Hospital (unhealthy) 97 907 
Rome # 2002-2007 Hospital 98 >18 275  Hospital (unhealthy) 94 293 
Western Europe # 2000-2005 Hospital 82 NA 1,701  Hospital (unhealthy) 68 1,993 
Germany-Heidelberg #  1998-2000 Hospital 96 <80 246  Community 62.4 769 
North America 
         
New York║  # 1981-1990 Hospital 91 21-80 1,118  Hospital (unhealthy) 97 906 
Seattle, WA  1985–1995 Cancer 
registry 
54.4, 
63.3¶ 18–65 407  Random digit dialing 
63.0, 
60.9¶ 607 
Iowa  1993–2006 Hospital 87 >18 546  Hospital (unhealthy) 92 759 
North Carolina  1994–1997 Hospital 88 >17 180  Hospital (unhealthy) 86 202 
Tampa, FL  1994–2003 Hospital 98 ≥18 207  
Cancer screening 
clinic 
(healthy) 
90 897 
Los Angeles, CA  1999–2004 Cancer 
registry 49 18–65 417  
Households 
Neighborhood 67.5 1,005 
Houston, TX 2001-2006 Hospital 95 >18 830  Hospital visitors >80 865 
Boston, MA  # 1999-2003 Hospital 88.7 >18 584  Resident list 48.7 659 
     US multicenter (New York, San  
     Francisco, New Jersey, Atlanta) ||# 1983-1984 
Cancer 
registry 75 18-79 1,114  
Random digit dialling, 
health care financing 
administration rosters 
76 1,268 
Seattle-Leo, WA # 1983-1987 Cancer 
registry 81 20-74 634  Random digit dialing 75 445 
North Carolina pop-based # 2002-2006 Cancer 
registry 82 20-80 1,368  DMV files 61 1,396 
Latin America 
         
Puerto Rico  1992–1995 Cancer 
registry 71 21–79 350  Residential records 83 521 
Latin America (Buenos Aires, Havana, 
Goiãnia, Pelotas, Porto Alegre, Rio de 
Janeiro, São Paulo)║ (NA) 
2000–2003 Hospital 95 15–79 2,191  Hospital (unhealthy) 86 1,706 
Sao Paulo║ # 2002-2007 Hospital >95 17–96 1,288  Hospital (unhealthy) >95 1,076 
International 
         
International (Italy, Spain, Ireland, 
Poland, Canada, Australia, Cuba, 
India, Sudan)║ 
1992–1997 Hospital 88.7 NA 1,559  Hospital/ Community 87.3 1,676 
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Table 1. Summary of individual studies in INHANCE consortium pooled data version 1.4, by region and study period 
 
 
 
 
 
*INHANCE = International Head and Neck Cancer Epidemiology; NA = not applicable/non available. 
‡: All studies frequency matched control subjects to case subjects on age and sex. Additional frequency matching factors included study center (Italy, Central Europe, 
Latin America, and International multicenter studies), hospital (France and Sao Paulo study), ethnicity (Tampa and US multicenter studies), and neighborhood or city 
of residence (Los Angeles and Sao Paulo study).  
§: Participation rate was not formally assessed, estimated response rate reported.  
||: Multicenter study.  
¶: Two response rates are reported because data were collected in two population-based case–control studies, the first from 1985–1989 among men and the second 
from 1990–1995 among men and women 
# Study added to the INHANCE 1.0 dataset 
X information not available TO CHECK 
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Tables 2: Selected characteristics of the head and neck case 
subjects and controls subjects§ from the INHANCE 
consortium  
 
Case  Controls 
 
n % n % 
Total 4 093  13 416  
Age Categories 
    
     <40 331 8.1 1149 8.6 
     40-<45 235 5.7 939 7.0 
     45-<50 369 9.0 1353 10.1 
     50-<55 521 12.7 1876 14.0 
     55-<60 628 15.3 2065 15.4 
     60-<65 597 14.6 1927 14.4 
     65-<70 519 12.7 1806 13.5 
     70-<75 476 11.6 1378 10.3 
     >=75 417 10.2 923 6.9 
     p* <0.0001 
Sex 
    
     Women 1678 41.0 5875 43.8 
     Men 2415 59.0 7541 56.2 
     p* 0.002 
Race 
    
     White 2655 64.9 9968 74.3 
     Black 273 6.7 655 4.9 
     Hispanic 103 2.5 330 2.5 
     Asian 111 2.7 472 3.5 
     Other 30 0.7 110 0.8 
     Brazilian‡ 921 22.5 1881 14.0 
     p* <0.0001 
Education 
    
     None 129 3.4 272 2.1 
     Junior high school 1447 37.6 4533 35.0 
     Some high school 560 14.6 1856 14.3 
     High School Graduate 513 13.3 1674 12.9 
     Vocational, some college 602 15.7 2343 18.1 
     Some graduate 596 15.5 2284 17.6 
     Missing# 246  454  
     p* <0.0001 
Subsite 
    
     Oral cavity 1327 32.4   
     Oropharynx 1179 28.8   
     Hypopharynx 230 5.6   
     Oral cavity/Pharynx NOS 488 11.9   
     Larynx 797 19.5   
     Head and neck overlap 72 1.8   
* Chi-square two-sided test 
# Rome does not have information on education 
§
 Missing for age, sex, race and subsite as well as users of pipe 
or cigar or chewed 
 tobacco or snuffed tobacco or straw cigarettes were excluded 
‡ only cases and controls from Sao Paulo and Latin America 
study. 
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Tables 3. Lifetime average daily number of cigarettes smoked and the risk of HNC, among the overall population and among never alcohol drinkers, in 
the INHANCE consortium 
 Overall1 Never alcohol drinkers2 Overall without Oropharyngeal cases3 
Number of cigarettes 
smoked per day Cases Controls OR# 95% CI Cases Controls OR# 95% CI Cases Controls OR# 95% CI 
Never 1939 9239 1.00 Ref 724 2836 1.00 Ref 1635 8821 1.00 Ref 
>0-3 250 793 1.52 (1.21, 1.90) 41 123 1.35 (0.83, 2.18) 212 779 1.56 (1.25, 1.93) 
>3-5 314 710 2.14 (1.73, 2.65) 38 89 2.01 (1.22, 3.31) 278 680 2.30 (1.88, 2.81) 
>5-10 1258 2215 2.60 (2.00, 3.40) 131 286 2.12 (1.48, 3.02) 1137 2125 2.98 (2.31, 3.82) 
Missing 332 459   11 13   299 451   
P value   <0.01    <0.01    <0.01  
P for Heterogeneity across 
studies   <0.01    <0.01    <0.01  
1
 Adjusted on age (categorical), sex, race, education level, centers and drinks per day (categorical). The 23 studies were included. 
2
 Adjusted on age (categorical), sex, race, education level and centers. The Switzerland, New York multicenter, Iowa, Los Angeles, Houston, Puerto Rico, Latin 
America, IARC multicenter, Sao Paulo, Western Europe and North Carolina pop-based studies were included. 
3Adjusted on age (categorical), sex, race, education level, centers and drinks per day. The 23 studies, except for the North Carolina and Tampa studies, were  
included. 
# Random effect model used 
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Tables 4. Lifetime average daily number of cigarettes smoked and the risk of HNC by subsite of cancer, in the INHANCE consortium 
 Oral cavity~ Hypopharynx* Oropharynx|| Larynx# 
Daily number of 
cigarette 
smoked  
Cases Controls OR& 95% CI Cases Controls OR& 95% CI Cases Controls OR& 95% CI Cases Controls OR& 95% CI 
Never 653 6309 1.00  38 3521 1.00  520 7368 1.00  203 6010 1.00  
>0-3 62 548 1.48 (1.04, 2.09) 13 3443 2.43 (1.23, 4.79) 70 661 1.57 (1.10, 2.23) 58 581 2.68 (1.82, 3.95) 
>3-5 79 474 2.23 (1.45, 3.42) 17 310 3.35 (1.78, 6.29) 64 528 2.17 (1.53, 3.06) 74 518 3.48 (2.40, 5.05) 
>5-10 291 1501 2.18 (1.68, 2.83) 71 1032 4.38 (2.82,6.82) 323 1724 2.85 (1.89, 4.08) 309 1543 5.21 (4.07, 6.68) 
Missing 104 407   8 244   51 398   92 324   
P value 
  <0.01    <0.01    <0.01    <0.01  
P for 
Heterogeneity 
across studies 
  <0.01    <0.01    <0.01    <0.01  
                 
Adjusted on age (categorical), race, education level, centers and drinks per day (categorical) 
~ The Aviano, Boston, Los Angeles, Milan, North Carolina, Rome, Switzerland, Tampa, Seattle-LEO and Germany-Heidelberg studies were NOT included 
* Only Aviano, Italy multicenter, New York, Latin America, US multicenter, Seattle-LEO, and Western Europe studies were included 
|| The Milan, Central Europe,  Seattle, North Carolina, Tampa, Boston,, and Germany-Heidelberg studies were NOT included 
# Only Milan, Central Europe, Italy Multicenter, New York,, Iowa, Los Angeles, Latin America, Boston, Rome, Sao Paulo, Seattle-LEO, Western Europe, Germany-Heidelberg and 
North Carolina pop-based studies were included. 
& Random effect models 
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Tables 5: Lifetime average daily number of cigarettes smoked and the risk of HNC by gender, in the INHANCE 
consortium 
 
Men1  Women2 
Daily Number of cigarette 
smoked  Cases Controls OR# 95% CI  Cases Controls OR# 95% CI 
Never 853 4099 1.00   882 3763 1.00  
>0-3 141 480 1.39 (0.96, 2.01)  101 278 1.77 (1.30, 2.40) 
>3-5 160 409 2.05 (1.39, 3.02)  118 200 2.74 (2.01, 3.74) 
>5-10 854 1420 2.83 (2.01 3.98)  330 556 2.67 (2.02, 3.53) 
Missing 235 250    84 180   
P value   <0.01     <0.01  
P for Heterogeneity across 
studies   <0.01     <0.01  
Adjusted on age (categorical), race, education level, centers and drinks per day (categorical)   
1 
 The Boston, North Carolina, Tampa, Switzerland and Seattle-LEO studies were NOT included 
2
 The Boston, Milan, Rome, Tampa and Germany-Heidelberg studies were NOT included 
# Random effect models 
 
Tables 6: Adjusted OR (OR, 95% Confidence intervals) of HNC by lifetime average daily number of 
cigarettes smoked combined with duration of cigarette smoking in years, in the INHANCE consortium 
 Cases Controls OR^ 95% CI 
Never smokers 1163 4329 1.00 Ref 
>0-3 cig for <=10yrs 53 199 1.04 (0.75; 1.43) 
>0-3 cig for >10-20yrs 27 77 1.39 (0.88, 2.20) 
>0-3 cig for >20-30yrs 29 79 1.30 (0.83, 2.03) 
>0-3 cig for >30yrs 76 104 2.64 (1.92, 3.63) 
>3-5 cig for <=10yrs 30 98 1.04 (0.68, 1.59) 
>3-5 cig for >10-20yrs 22 70 1.19 (0.72, 1.96) 
>3-5 cig for >20-30yrs 37 55 2.35 (1.52, 3.65) 
>3-5 cig for >30yrs 101 105 2.89 (2.13, 3.91) 
>5-10 cig for <=10yrs 52 167 1.06 (0.76, 1.47) 
>5-10 cig for >10-20yrs 55 220 0.94 (0.68, 1.29) 
>5-10 cig for >20-30yrs 130 221 1.91 (1.49, 2.43) 
>5-10 cig for >30yrs 541 412 4.17 (3.54, 4.90) 
Missing 229 164   
P for Heterogeneity   0.05  
P for trend   <0.01  
Adjusted on age (categorical), race, education level, centers and drinks per day (categorical) 
1 
 The Los Angeles, International Multicenter, US multicenter, Sao Paulo, Western Europe, North Carolina (pop 
based) studies were included 
^Fixed effect model 
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Figure 1: Forest plot of the risk of HNC associated with lifetime consumption of 3 to 5 cigarettes per day compared to never smokers, in the INHANCE Consortium 
   
